Novel composite material applied to repair of cartilage damage

Abstract

The invention discloses a novel composite material applied to the repair of cartilage damage. The novel composite material is composed of an extracellular matrix, chondrogenic proteins and human umbilical cord mesenchymal stem cells. The extracellular matrix is originated from a placenta and is compounded with the chondrogenic proteins to form an extracellular matrix composite material; and the human umbilical cord mesenchymal stem cells are originated from human umbilical cord tissue and placental tissue. The human umbilical cord mesenchymal stem cells of the invention have good repair effecton cartilage damage; the placenta-derived extracellular matrix material is rich in collagen and elastic fibers, and various cytokines are retained during the preparation process of the novel composite material, so a good growth and differentiation microenvironment is provided for inoculated stem cells; and through the combination of the human umbilical cord mesenchymal stem cells and the placenta-derived extracellular matrix material, the novel composite material is greatly improved in the ability of repairing damaged cartilage compared with traditional materials.

Description

technical field [0001] The invention relates to the field of biomaterials, in particular to a novel composite material applied to repairing cartilage damage and a preparation method thereof. Background technique [0002] With the aging of the global population, the increase of chronic diseases and sports trauma, articular cartilage damage endangers the health of tens of millions of people, and has gradually become the main cause of human disability. In recent years, the repair of articular cartilage damage has been a hot spot in orthopedic research. Due to the weak self-repair ability of articular cartilage after injury, although the current treatment methods and methods can relieve pain and improve dysfunction to varying degrees, the curative effect is short-lived, and the new cartilage tissue at the damaged site will eventually degenerate or even die, making it difficult to obtain satisfactory long-term results. Phase clinical efficacy. Tissue engineering and regenerativ...

AI Technical Summary

Problems solved by technology

At present, the common sources of extracellular matrix (ECM) include ECM after decellularization of porcine chondrocytes, ECM after allogeneic chondrocytes, and ECM-like ECM produced by using type II collagen and aminoglycans. ACTM biological materials, etc., have problems such as short therapeutic effect time and poor repair ability

Images